Table 1 Patient baseline characteristics
Number of patients | % of patients | |
|---|---|---|
Median age: 56 years | ||
Range: 26–86 years | ||
Histology | ||
Ductal carcinoma | 172 | 85.1 |
Lobular carcinoma | 23 | 35.4 |
Other | 7 | 3.5 |
Subtype | ||
Luminal A | 60 | 29.7 |
Luminal B | 89 | 44.1 |
HER2-enriched | 14 | 6.9 |
TNBC | 39 | 19.3 |
ER status | ||
Positive | 145 | 71.8 |
Negative | 57 | 28.2 |
PgR status | ||
Positive | 131 | 64.9 |
Negative | 71 | 35.1 |
HER2 status | ||
Positive | 55 | 27.2 |
Negative | 147 | 72.8 |
Ki67 | ||
< 20% | 74 | 36.6 |
≥ 20% | 127 | 62.9 |
Unk | 1 | 0.5 |
Stage | ||
I | 42 | 20.8 |
II | 111 | 55 |
III | 49 | 24.3 |
T stage | ||
1 | 64 | 31.7 |
2 | 89 | 44 |
3 | 21 | 10.4 |
4 | 27 | 13.4 |
Unk | 1 | 0.5 |
N stage | ||
0 | 101 | 50 |
1 | 82 | 40.6 |
2 | 10 | 5 |
3 | 6 | 3 |
Unk | 3 | 1.4 |
Tumor grade | ||
G1 | 5 | 2.5 |
G2 | 100 | 49.5 |
G3 | 91 | 45 |
Unk | 6 | 3 |
Lymphovascular invasion | ||
Yes | 41 | 20.3 |
No | 156 | 77.2 |
Unk | 5 | 2.5 |
Neoadjuvant chemotherapy (NAC) | ||
Yes | 126 | 72.4 |
No | 76 | 37.6 |
Type of NAC (N = 126) | ||
EC → Taxane | 94 | 74.6 |
FEC → Taxane | 21 | 16.7 |
EC → CBDCA-Ptx | 6 | 4.8 |
Other | 5 | 4 |
Pathological complete response (N = 126) | ||
Yes | 43 | 34.1 |
No | 83 | 65.9 |
Adjuvant chemotherapy (AC) | ||
Yes | 43 | 21.3 |
No | 159 | 78.7 |
Type of AC (N = 43) | ||
EC → Taxane | 11 | 25.6 |
FEC → Taxane | 20 | 9.9 |
Capecitabine | 5 | 11.6 |
Other | 7 | 3.5 |
Trastuzumab | ||
Yes | 53 | 26.2 |
No | 149 | 73.8 |
Radiotherapy | ||
Yes | 174 | 86.1 |
No | 28 | 13.9 |
Hormonotherapy | ||
Yes | 149 | 73.2 |
No | 54 | 26.8 |
Type of hormonotherapy | ||
SERM | 56 | 37.6 |
AI | 79 | 53 |
SERM + AI | 14 | 9.4 |
Relapse | ||
Yes | 28 | 13.9 |
No | 174 | 86.1 |